Benzathine Penicillin G: Syphilis Treatment by Stage

Benzathine penicillin G is one of the most successful drugs in medical history: a single intramuscular injection cures early-stage syphilis, and the bacterium has shown no clinically significant resistance to penicillin after 80 years of use. This page covers the specific dosing by stage, why the IV route is required for neurosyphilis, the Jarisch-Herxheimer reaction, alternatives for penicillin allergy, and how to know if treatment worked.

Why T. pallidum Has Never Developed Penicillin Resistance
Primary, Secondary, and Early Latent: 2.4M Units IM ×1
Late Latent and Unknown Duration: Weekly ×3
Tertiary and Neurosyphilis: Aqueous Penicillin G IV
The Jarisch-Herxheimer Reaction: Mechanism and Management
Alternatives for Penicillin Allergy
Treatment Failure and Retreatment
Monitoring Treatment: RPR Titer Decline
Key Research Papers
Featured Videos

1. Why T. pallidum Has Never Developed Penicillin Resistance

In 80-plus years of widespread penicillin use, Treponema pallidum has never acquired clinically significant resistance to penicillin. This is exceptional. Neisseria gonorrhoeae, another sexually transmitted bacterium, developed penicillin resistance within years of penicillin's introduction and is now resistant to multiple antibiotic classes. T. pallidum has not budged.

The reasons are not fully understood but probably involve several factors:

Minimal genome, minimal adaptability. T. pallidum has one of the smallest genomes of any pathogenic bacterium (~1.14 Mb, encoding ~1,000 genes). It has discarded most of its metabolic capabilities, outsourcing them to the host. This stripped-down genome leaves little room for acquiring or maintaining resistance genes, which typically require additional metabolic machinery.
Cannot be cultured in the lab. Antibiotic resistance typically evolves through laboratory selection or widespread use in agricultural settings. T. pallidum cannot be grown outside a living host, which limits the opportunities for resistance development through the usual routes.
No horizontal gene transfer detected. Many bacteria spread resistance genes through plasmids and other mobile genetic elements shared between organisms. This mechanism has not been documented for T. pallidum.
Penicillin mechanism is difficult to circumvent. Penicillin kills bacteria by binding to penicillin-binding proteins (PBPs) and blocking cell wall synthesis. Resistance requires either producing beta-lactamase enzymes (which destroy penicillin) or altering PBPs so penicillin cannot bind. T. pallidum appears unable to accomplish either.

This sustained susceptibility is one of the most important facts in infectious disease. Unlike virtually every other major bacterial pathogen, syphilis treatment has not had to chase resistance.

2. Primary, Secondary, and Early Latent Syphilis: 2.4M Units IM ×1

For all early-stage syphilis (primary chancre, secondary rash, or early latent infection within one year of acquisition), the treatment is a single intramuscular injection of benzathine penicillin G 2.4 million units.

Practical details:

Formulation: Benzathine penicillin G (Bicillin L-A) — not procaine penicillin G and not amoxicillin, which achieve different pharmacokinetic profiles. Dispensing errors (using Bicillin C-R, which contains procaine penicillin and provides half the benzathine dose) have caused treatment failures and are a recognized safety issue.
Injection site: Intramuscularly into the gluteal muscle or the vastus lateralis (outer thigh). The injection is viscous and may cause brief discomfort.
Pharmacokinetics: Benzathine penicillin provides sustained low-level penicillin G concentrations for two to three weeks from a single injection. This is precisely what is needed: T. pallidum divides slowly (approximately every 30 to 33 hours), and penicillin must be present continuously long enough to kill all organisms.
Efficacy: A single dose cures primary and secondary syphilis in approximately 95% or more of cases. Early latent syphilis cure rates are somewhat lower and require careful serologic follow-up.

3. Late Latent and Unknown Duration: Weekly ×3

For late latent syphilis (more than one year after infection) or syphilis of unknown duration, the standard regimen is three weekly injections of benzathine penicillin G 2.4 million units IM, one week apart (weeks 0, 1, and 2), for a total of 7.2 million units.

Why three doses instead of one?

The drug concentration from a single injection may wane before it has had sufficient time to eliminate spirochetes that are sequestered in less vascular tissues (bone, fibrous scar tissue, the central nervous system).
With longer duration of infection before treatment, organisms are more widely distributed and potentially in more metabolically quiescent states.
The three-dose regimen provides 21 continuous days of treponemicidal drug levels from the first injection, with the second and third doses extending coverage.

Missing a dose by more than a few days may require starting the course over. Patients should be counseled to keep all three appointments.

4. Tertiary and Neurosyphilis: Aqueous Penicillin G IV

Neurosyphilis and other forms of tertiary syphilis require a fundamentally different treatment approach: intravenous aqueous crystalline penicillin G at high doses for 10 to 14 days.

Why not benzathine penicillin G for neurosyphilis? Benzathine penicillin G achieves adequate blood and tissue levels but does not reliably penetrate the blood-brain barrier at treponemicidal concentrations. Studies measuring penicillin levels in cerebrospinal fluid after benzathine penicillin G injection found concentrations often below the minimum inhibitory concentration for T. pallidum. The IV formulation, by contrast, achieves CSF levels well above the MIC.

The neurosyphilis regimen:

Aqueous crystalline penicillin G 18–24 million units per day, given as 3 to 4 million units every 4 hours by continuous IV infusion, for 10 to 14 days
Alternative if IV access is difficult: Procaine penicillin G 2.4 million units IM daily PLUS probenecid 500 mg orally four times daily, both for 10 to 14 days. Probenecid blocks renal tubular secretion of penicillin, increasing and prolonging blood levels to achieve adequate CNS penetration.
After completing IV treatment, some experts recommend following with benzathine penicillin G 2.4 million units IM weekly ×3 to ensure adequate tissue levels, though this is not universally required.

For ocular syphilis (uveitis, retinitis) and otosyphilis (sudden sensorineural hearing loss), the same IV penicillin neurosyphilis regimen is recommended, since these involve analogous sanctuary-site penetration challenges.

5. The Jarisch-Herxheimer Reaction: Mechanism and Management

Within two to eight hours of the first penicillin dose for syphilis, 50 to 75% of patients with primary or secondary syphilis experience the Jarisch-Herxheimer reaction (JHR) — a febrile, flu-like syndrome that can be alarming if not anticipated.

What it feels like:

Fever rising to 39–40°C (102–104°F), often with chills and sweats
Headache, myalgias (muscle aches), and malaise
Temporary worsening or flaring of the syphilitic rash or other active lesions
Onset within 2–8 hours; peak at 6–8 hours; resolution within 12–24 hours in most cases

What causes it: The JHR is not an allergic reaction to penicillin. It is caused by the rapid release of inflammatory mediators — particularly tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-8 (IL-8) — in response to the sudden killing of large numbers of spirochetes and the release of their cell-wall lipoproteins. These lipoproteins trigger an acute inflammatory cascade, essentially a brief, intense version of the same response that causes sepsis symptoms from gram-negative bacteria.

Management:

Antipyretics (acetaminophen 650–1000 mg) provide symptomatic relief and can be taken prophylactically before the injection
Adequate hydration
Reassurance that this is expected and self-limiting
Do not stop the antibiotic. The JHR is not a reason to discontinue penicillin. Stopping treatment would leave the syphilis incompletely treated.

Groups requiring special caution:

Pregnant women: The JHR can trigger uterine contractions and, rarely, premature labor or fetal distress. Women in the second or third trimester being treated for syphilis should be monitored in a healthcare facility for several hours after the injection.
Neurosyphilis patients: Transient worsening of neurologic symptoms is possible; patients should be warned.
Cardiovascular syphilis patients: The acute inflammatory response can transiently worsen aortic valve regurgitation.

6. Alternatives for Penicillin Allergy

For non-pregnant patients with documented penicillin allergy who cannot undergo desensitization, the following alternatives are used, though with less supporting evidence than penicillin:

Doxycycline:

Primary/secondary/early latent: 100 mg orally twice daily for 14 days
Late latent: 100 mg orally twice daily for 28 days
Advantages: oral, inexpensive, widely available
Limitations: must not be used in pregnancy; requires patient adherence over 14–28 days vs. a single injection; data on efficacy, while supportive, derive largely from case series rather than randomized trials

Ceftriaxone:

1–2 g IM or IV daily for 10–14 days
Advantages: parenteral (ensuring drug delivery), some CNS penetration, low cross-reactivity with penicillin (<2%)
Limitations: requires daily injections or IV access; evidence is mainly case series; optimal dose and duration uncertain

Azithromycin: Previously used as an alternative but now no longer recommended for syphilis treatment due to documented macrolide resistance (the A2058G and A2059G mutations in 23S rRNA) now prevalent in many geographic areas including the US, UK, and Australia. A patient treated with azithromycin in an area with resistance has a high probability of treatment failure.

For pregnant women with penicillin allergy: Penicillin desensitization is mandatory. Alternative regimens have not been proven to prevent congenital syphilis.

7. Treatment Failure and Retreatment

Treatment failure is defined as:

Failure of RPR/VDRL titer to decline fourfold within 6 to 12 months of treatment for early syphilis
A fourfold or greater rise in RPR/VDRL titer after initial decline (suggesting reinfection or reactivation)
Persistence or development of new clinical signs of syphilis

When treatment failure is suspected:

Rule out reinfection (the most common cause of rising titers — the patient has been exposed again)
Evaluate for neurosyphilis with lumbar puncture (even without neurologic symptoms)
Treat as late latent syphilis (benzathine penicillin G 2.4 million units weekly ×3) if neurosyphilis is excluded
Treat as neurosyphilis (aqueous penicillin G IV) if CSF is abnormal

True treatment failure with benzathine penicillin G (not reinfection, not the JHR, not the expected slow titer decline of late latent syphilis) is rare. Most apparent failures involve reinfection, incomplete initial regimens, or failure to achieve the fourfold titer definition due to the slow serologic response in late-stage disease.

8. Monitoring Treatment: RPR Titer Decline

After treatment, RPR or VDRL titers should be checked at regular intervals. The goal is to confirm that the titer is declining, indicating successful treatment. This is the only objective measure of treatment efficacy available for syphilis.

Expected titer responses:

Early syphilis (primary, secondary, early latent): Titer should decline fourfold within 6 months; many patients achieve eightfold or greater decline within 12 months; some reach serofast status (stable low-positive titer, typically 1:1 to 1:4, that does not fully revert to negative)
Late latent syphilis: Titer decline is slower; a fourfold decline within 12 to 24 months is considered adequate
Neurosyphilis: CSF-VDRL and CSF cell count should be rechecked at 3 to 6 month intervals after treatment

Serofast state: A small percentage of patients, especially those treated for late-stage disease, remain with a persistently positive non-treponemal test (usually at low titer, 1:1 to 1:4) after otherwise successful treatment. This does not represent ongoing infection — treponemal tests are positive for life, and some patients retain detectable but non-rising non-treponemal antibodies. The key distinction: in serofast status, the titer is stable and low; in treatment failure or reinfection, the titer rises fourfold or more.

Recommended follow-up schedule after treatment: clinical and serologic evaluation at 6 and 12 months for early syphilis; at 6, 12, and 24 months for late latent; more frequently for patients with HIV co-infection.

Key Research Papers

Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1–187. PMID 34292926
Stamm LV. Syphilis: antibiotic treatment and resistance. Epidemiol Infect. 2015;143(8):1567–1574. PMID 25358466
Lukehart SA, Hook EW, Baker-Zander SA, Collier AC, Critchlow CW, Handsfield HH. Invasion of the central nervous system by Treponema pallidum: implications for diagnosis and treatment. Ann Intern Med. 1988;109(11):855–862. PMID 3058170
Rolfs RT, Joesoef MR, Hendershot EF, et al. A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. N Engl J Med. 1997;337(5):307–314. PMID 9235493
Marra CM, Maxwell CL, Tantalo LC, et al. Normalization of serum rapid plasma reagin titer predicts normalization of cerebrospinal fluid and clinical abnormalities after treatment of neurosyphilis. Clin Infect Dis. 2008;47(7):893–899. PMID 18715148
Bolan GA, Sparling PF, Wasserheit JN. The emerging threat of untreatable gonococcal infection. N Engl J Med. 2012;366(6):485–487. PMID 22316442
Sexually Transmitted Disease Surveillance 2022. US Dept of Health and Human Services; 2023. PMID 37791576
Bachmann LH, Desmond RA, Stephens J, et al. Duration of persistence of gonococcal DNA detected by ligase chain reaction in men and women following recommended therapy for uncomplicated gonorrhea. J Clin Microbiol. 2002;40(9):3596. PMID 12202605
Myint M, Bashiri H, Harrington RD, Marra CM. Relapse of secondary syphilis after benzathine penicillin G: molecular analysis. Sex Transm Dis. 2004;31(4):196–199. PMID 15028940
Ghanem KG, Ram S, Rice PA. The modern epidemic of syphilis. N Engl J Med. 2020;382(9):845–854. PMID 32101666

Back to Table of Contents

Connections